Selcia




Contract Research Services in Integrated Drug Discovery and Custom Radiolabelling.

A leading worldwide provider of integrated drug discovery, medicinal chemistry and GMP certified 14C custom radiolabelling services, Selcia is a self-funded, profitable, private company with around 80 employees operating from state-of-the-art laboratories. SELCIA DISCOVERY offers integrated drug discovery services including screening biology, medicinal chemistry, ADME/PK and in vivo PK work

Contact Selcia via their website


News archive

16/03/2017   Selcia funded by MedCity for QMU collaboration under Collaborate to Innovate scheme...more
01/03/2017   Selcia Discovery scientists to support Cypralis Alzheimers’s project...more
10/02/2017   Selcia, Cypralis and Gilead Sciences publish in Journal of Medicinal Chemistry...more
23/01/2017   Selcia Discovery services assisted Cypralis Innovate UK Early Stage award...more
23/01/2017   Meet Selcia at several upcoming conferences...more
11/01/2017   Meet Selcia at several forthcoming conferences in 2017...more

11/08/2016   Selcia’s Fragment Library is now available via BioAscent Discovery’s “Compound Cloud”...more
25/05/2016   Selcia Opens New Dedicated 14C GMP API Facility...more
29/02/2016   Selcia Celebrates Anniversary of the Discovery of Carbon-14...more
25/01/2016   Selcia's Dr Hans Fliri Features in Drug Target Review...more

07/12/2015   Selcia spin-out Cypralis announces collaboration with Johnson & Johnson Innovation...more
30/11/2015   University of Edinburgh and Selcia Achieve Key Milestones targeting Sleeping Sickness...more
02/11/2015   Selcia will provide integrated drug discovery services to spin-out Cypralis...more
20/10/2015   Selcia constructs new 14C GMP API manufacturing suite ...more
07/10/2015   Selcia Chemists Co-author Poster on Anti-Infectives...more
24/09/2015   Selcia and UCL publish paper in Open Biology...more
10/09/2015   Selcia Publishes Prolyl Isomerase White Paper...more
30/06/2015   Selcia Renews French Research Tax Credit Accreditation...more
26/06/2015   Selcia joins the Safety Alliance, a network of selected high-quality CROs accross Europe....more
09/01/2015   Selcia Scientists Published in Nature...more

03/02/2014   University of Edinburgh and Selcia in bid to target sleeping sickness...more

25/11/2013   Selcia Celebrates Successful MHRA Inspection of its GMP Radiolabelling Facility...more
08/10/2013   Selcia Appoints New Director of Discovery...more
02/09/2013   Selcia and Cantab Announce Drug Discovery Collaboration ...more
13/06/2013   Selcia is attending the Anglonordic Biotech Conference...more
03/04/2013   Selcia in sp2-Magazine: Developing Drugs Targeting Peptidyl-Prolyl Isomerases ...more
07/01/2013   Selcia Achieves French R&D Tax Credit Accreditation...more

27/11/2012   Selcia introduces new Prolyl Isomerase screening service...more
30/10/2012   Selcia receives GLP re-certification from the MHRA...more
08/10/2012   Selcia Holdings and NeuroVive Announce development of three lead drug candidates...more
20/09/2012   Selcia Patents Drug Discovery Platform...more
30/07/2012   Selcia exploits in-house IP with demerger move...more
11/06/2012   Selcia celebrates twenty years of radiosynthesis...more
25/04/2012   Selcia feature in SP2 magazine...more
18/04/2012   Selcia and Heptares Therapeutics Announce New Fragment Screening Collaboration...more

24/11/2011   Selcia Doubles Capacity of 14C GMP Radiolabelled API Production for Human Studies ...more
19/09/2011   Selcia and NeuroVive to develop new medicines...more
29/09/2011   New Selcia Fragment Screening Posters...more
22/08/2011   New Biotech Laboratory Expands Selcia’s US Operation...more
31/05/2011   Simon Bury joins Selcia to expand drug discovery offering ...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code